Companies · Biotechnology
BOSTON · Biotechnology
Diligence memoA one-page analyst read on LikeMinds, Inc./DE — recommendation, valuation, rhythm, risks.→LikeMinds, Inc./DE looks under-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
LikeMinds, Inc./DE is one of 4291 Biotechnology companies tracked from BOSTON. By capital raised it ranks mid-pack (ahead of 48% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.
Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 48% of sector peers (real $). Modeled value above 33% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #201 of 216.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| TRACT Therapeutics, Inc. | Series A | $15.0M | $542.3M | 3.00× |
| Arrakis Therapeutics, Inc. | Series A | $28.2M | $542.3M | 3.00× |
| TechAccel, LLC | Series A | $15.0M | $541.9M | 3.00× |
| Trident Labs, Inc. | Series A | $14.0M | $506.1M | 2.80× |
| Meissa Vaccines Inc | Series A | $15.2M | $503.1M | 2.78× |
| Vibe Bioscience Ltd. | Series A | $13.9M | $501.1M | 2.77× |
| Trovagene, Inc. | Series A | $45.3M | $488.0M | 2.70× |
| Equinox, Inc. | Series A | $34.7M | $485.2M | 2.68× |
| Taiga Biotechnologies, Inc. | Series A | $37.9M | $484.6M | 2.68× |
| Aruna Biomedical Inc | Series A | $22.4M | $480.5M | 2.66× |
| Vibe Bioscience Corp | Series A | $13.7M | $476.8M | 2.64× |
| Adarza BioSystems, Inc. | Series A | $31.5M | $461.9M | 2.56× |
| LikeMinds, Inc./DE this company | Series A | $6.4M | $26.7M | 0.15× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series A | $5.2M | 2018-09-12 | $23.7M | $188.8M | 90% |
| Series A | $1.1M | 2021-05-28 | $5.2M | $26.7M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Paul G. Sekhri | — | 1 other | 2018-09 |
| Peter G. Savas | — | 1 other | 2018-09 |
| Gary G. Frashier | — | — | 2018-09 |
| Henry G. Brem | — | — | 2018-09 |
| Kenneth G. Rice | — | — | 2018-09 |
| Robert G. Langer | — | — | 2018-09 |
| Robert G. Van Nostrand | — | — | 2018-09 |
| Vicki G. Zikopoulou | — | — | 2021-05 |
LikeMinds, Inc./DE is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Alseres Pharmaceuticals Inc /De | Biotechnology | Seed | $5.9M | $44.4M | network1 shared operator · same sector |
| Intellistem, Inc. | Biotechnology | Series A | $6.2M | $25.6M | same sector · same stage |
| MB Holdings 2025, Inc. | Biotechnology | Series A | $6.2M | $23.9M | same sector · same stage |
| Aveta Biomics, Inc. | Biotechnology | Series A | $6.2M | $24.4M | same sector · same stage |
| SimBioSys, Inc. | Biotechnology | Series A | $6.1M | $21.9M | same sector · same stage |
| Amplifi Vascular, Inc. | Biotechnology | Series A | $6.7M | $29.0M | same sector · same stage |
| Cynaptec Pharmaceuticals, Inc. | Biotechnology | Series A | $6.0M | $21.6M | same sector · same stage |
| Enquyst Technologies Inc. | Biotechnology | Series A | $6.0M | $20.1M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Novamind Inc. | Biotechnology | Series A | $66.5M | 87% |
| Novamind Ventures Inc. | Biotechnology | Seed | $78.2M | 86% |
| Ideaya Biosciences, Inc. | Biotechnology | Series C | $3.9B | 83% |
| Genome Insight, Inc. | Biotechnology | Series A | $39.9M | 83% |
| Sensearly Inc. | Biotechnology | Seed | $5.7M | 83% |
| AstralBio, Inc. | Biotechnology | Pre-Seed | $3.4M | 83% |
| Clearmind Medicine Inc. | Biotechnology | Seed | $15.1M | 83% |
| Senseonics Holdings, Inc. | Biotechnology | Series B | $98.8M | 82% |
See where LikeMinds, Inc./DE sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at LikeMinds, Inc./DE, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.